Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Gross Profit: 2009-2024

Historic Gross Profit for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $105.6 million.

  • Heron Therapeutics' Gross Profit rose 12.62% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.6 million, marking a year-over-year increase of 15.30%. This contributed to the annual value of $105.6 million for FY2024, which is 70.55% up from last year.
  • As of FY2024, Heron Therapeutics' Gross Profit stood at $105.6 million, which was up 70.55% from $61.9 million recorded in FY2023.
  • Heron Therapeutics' 5-year Gross Profit high stood at $105.6 million for FY2024, and its period low was -$833,000 during FY2021.
  • For the 3-year period, Heron Therapeutics' Gross Profit averaged around $73.5 million, with its median value being $61.9 million (2023).
  • As far as peak fluctuations go, Heron Therapeutics' Gross Profit crashed by 103.36% in 2021, and later skyrocketed by 6,438.30% in 2022.
  • Yearly analysis of 5 years shows Heron Therapeutics' Gross Profit stood at $24.8 million in 2020, then slumped by 103.36% to -$833,000 in 2021, then surged by 6,438.30% to $52.8 million in 2022, then rose by 17.31% to $61.9 million in 2023, then surged by 70.55% to $105.6 million in 2024.